GlobalData’s forecasts indicate a strong demand for small-molecule treatments for NSCLC in the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and China), with the market expected to surpass $15 billion by 2029, representing about 40% of the total NSCLC market.
Biswajit Podder, PhD, an Oncology and Hematology Analyst at GlobalData, remarks: “The approval of Tagrisso marked a significant shift in lung cancer treatment, particularly in the early stages where surgical removal of tumors is feasible, but recurrence is common (as seen in the Phase III ADAURA trial). Moreover, the groundbreaking results of the Phase III FLAURA trial set a new standard for the initial treatment of EGFR-mutated NSCLC. This ensures that a broader spectrum of patients can benefit from targeted small-molecule medications like Tagrisso.”
Advertisement
Additionally, 14 new small molecules are currently in Phase III clinical trials for lung cancer treatment, indicating a dynamic and robust clinical trial landscape.
Podder concludes: “Apart from the success of Tagrisso, AstraZeneca’s other promising pipeline drugs, notably Orpathys, are contributing to the company’s small-molecule lung cancer treatment portfolio. Orpathys is expected to generate $361 million in sales for lung cancer treatment by 2029. Furthermore, Lynparza, another small molecule from AstraZeneca, is undergoing clinical trials for lung cancer treatment. On the other hand, Eisai and Merck’s new asset, Kisplyx/Lenvima, is another major small molecule in Phase III development for NSCLC treatment, with projected sales of $176 million by 2029.”
Source: Medindia
Source link
#AstraZenecas #Tagrisso #Drug #Poised #Dominate #Lung #Cancer #Small #Molecule #Market
